Skip to main content
OpenTrials
Completed

NCT Number: NCT00918866

A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery Pressure

The purpose of this clinical research is to learn if DEFINITY® 416 will cause any adverse effects during Right Heart Catheterization. This research was requested by the FDA.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Northwestern Memorial Hospital, Chicago, Illinois, United States

Loading trial locations.

About this study

This Phase IV safety study will provide safety data on potential systemic and pulmonary hemodynamic effects caused by the administration of DEFINITY® in patients who are to undergo right heart cardiac catheterization for clinical reasons. Using a right heart catheter for direct measurements of pulmonary artery hemodynamics will allow accurate assessments of potential alterations of the pulmonary vasculature. This will be further investigated by the inclusion of two patient populations, one with a baseline pulmonary artery pressure < 35 mmHg, and one with elevated baseline pulmonary artery pressure. The addition of immune parameter measurements will assess a potential link between systemic and pulmonary alterations and potential immune reactions following DEFINITY® administration.

The inclusion of patients in this study is not based on a required echocardiogram with DEFINITY® administration because patients would be exposed to an unjustifiable risk of invasive right heart catheterization and are unlikely to consent to such a procedure. Therefore, patients undergoing heart catheterization for clinical reasons, or patients who are undergoing pulmonary artery hemodynamic assessments will be enrolled and receive DEFINITY® in this study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Appropriate candidate scheduled to undergo right heart catheterization and measurement of pulmonary artery hemodynamics for clinical reasons
  • Be male or female above the age of 18
  • Female patients who no longer have child-bearing potential
  • Women of Child-Bearing Potential(WOCBP) who:
  • are not pregnant and have been using an adequate and medically approved method of contraception
  • have a negative urine pregnancy test
  • Be able and willing to communicate effectively with study center personnel.

Exclusion criteria

  • Women who are pregnant or lactating
  • Known hypersensitivity or contraindication to or greater heart block
  • Previous heart transplant
  • Known right-to-left shunt (including atrial septal defect)
  • Severe pulmonary artery hypertension (i.e., > 75 mmHg
  • Current uncontrolled ventricular tachycardia
  • Second-degree or greater heart block
  • Any contraindications for the use of a right heart catheter

Treatment and study plan

Definity

Drug

one bolus dose of Definity per intravenous injection, 30-60 second injection, dose value calculation = maximum of 10 microliter/kg patient weight

Other names: Perflutren Lipid Microsphere

Primary outcomes

  1. Percent Change in Pulmonary Artery Pressure Change From 1 Minute Pre-dose to 31 - 35 Minutes Post Dose

    Time frame: 31-35 minutes minus baseline

    Percent change in pulmonary atery pressure change from immediately pre-dose to 31 - 35 minutes post dose

Secondary outcomes

  1. Immunology Panel- Complement 3A (C3A)

    Time frame: Out to 70 minutes

    Evaluate the Immunology Panel after the administration of DEFINITY

  2. Immunology Panel- Complement 5A(C5A)

    Time frame: Out to 70 minutes

    Evaluate the Immunology Panel after the administration of DEFINITY

  3. Immunology Panel- Interleuken-6

    Time frame: Out to 70 minutes

    Evaluate the Immunology Panel after the administration of DEFINITY

  4. Immunology Panel- Tryptase

    Time frame: Out to 70 minutes

    Evaluate the Immunology Panel after the administration of DEFINITY

Sponsors and collaborators

Lead sponsor

Lantheus Medical Imaging

Industry

Registry information

Official study title

A Phase IV, Open-Label Safety Evaluation of the Effect of DEFINITY® on Pulmonary Artery Hemodynamics in Patients With Normal and Increased Pulmonary Artery Pressure

Important dates

Study start
2009
Primary completion
2009
Study completion
2009
First posted
Jun 11, 2009
Registry last updated
Nov 24, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.